Variable allograft responses to pretreatment with donor splenocytes treated with mitomycin C in the rat.
In an attempt to investigate the nonspecificity of the effect of administration of donor splenocytes treated with mitomycin C (MMC) 7 days before transplantation in inducing immunological unresponsiveness, the survival rates of liver, heart, small bowel, and skin allografts were compared in the RT1-incompatible ACI(RT1a) to LEW(RT1l) rat combination. ACI donor splenocytes (3 x 10(6)) treated with MMC were administered i.p. or i.v. via the penile vein 7 days before transplantation. Both routes of administration prolonged the survival of hepatic allografts (greater than 87.2 +/- 22.2 days and greater than 78.9 +/- 28.2 days, respectively), compared with controls (10.6 +/- 0.5 days). Cardiac allograft survival in untreated controls was 6.0 +/- 0.4 days. A single i.v. injection of 3 x 10(6) donor splenocytes resulted in significantly prolonged survival (10.0 +/- 4.3 days), whereas i.p. injection showed rejection at a mean of 6.0 +/- 1.2 days. A single i.p. injection of 3 x 10(6) splenocytes did not increase survival of small bowel allografts (10.3 +/- 4.8 days), compared with controls (8.8 +/- 1.8 days). On the other hand, a single i.v. injection of donor splenocytes prior to transplantation significantly prolonged survival of small bowel allografts (13.4 +/- 3.5 days). No signs of graft-versus-host reaction (GVHR) were observed during these experiments. Neither a single i.p. nor a single i.v. injection of donor splenocytes resulted in prolonged survival of ACI-to-LEW skin allografts (6.3 +/- 0.8 days and 6.6 +/- 0.9 days, respectively), compared with controls (5.7 +/- 0.5 days). Interestingly, we confirmed the relative ease with which survival of hepatic allografts can be prolonged in the rat by donor antigen treatment alone, even in a strongly rejecting RT1-incompatible rat strain combination, in contrast to other organ allografts such as heart, small intestine, and skin. The discrepancy in survival of different organ allografts following pretreatment with donor splenocytes treated with MMC may be explained by a difference in the immunogenicity of the organs transplanted or other factors.
Yamaguchi
Y
Y
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710.
Harland
R
R
Wyble
C
C
Mori
K
K
Bollinger
R R
RR
D000818:Animals; D006085:Graft Survival / Q000187:drug effects*; D016027:Heart Transplantation; D007421:Intestine, Small / Q000637:transplantation; D016031:Liver Transplantation; D017710:Lymphocyte Transfusion; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011300:Preoperative Care / Q000379:methods; D051381:Rats; D011912:Rats, Inbred ACI; D011917:Rats, Inbred Lew; D016038:Skin Transplantation; D013154:Spleen
D008937:Mitomycins; D016685:Mitomycin